H. Lundbeck A/S (OMXCOP:HLUN_A) Completes Randomization in Phase III Dravet Trial
H. Lundbeck A/S said the last patient has been randomized in DEEp SEA, a global Phase III trial of bexicaserin for seizures in Dravet syndrome; over 100 participants enrolled, with an option to enter a 52-week open-label extension.Material DetailsContext by AI AnalystThis is a mid-cycle R&D milesto…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.